Institute of Pharmacology & Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, P. R. China.
Innovation Institute for Artificial Intelligence in Medicine, Zhejiang University, Hangzhou, 310018, P. R. China.
Adv Sci (Weinh). 2024 Sep;11(36):e2309459. doi: 10.1002/advs.202309459. Epub 2024 Jul 25.
Class IIa histone deacetylases (Class IIa HDACs) play critical roles in regulating essential cellular metabolism and inflammatory pathways. However, dissecting the specific roles of each class IIa HDAC isoform is hindered by the pan-inhibitory effect of current inhibitors and a lack of tools to probe their functions beyond epigenetic regulation. In this study, a novel PROTAC-based compound B4 is developed, which selectively targets and degrades HDAC7, resulting in the effective attenuation of a specific set of proinflammatory cytokines in both lipopolysaccharide (LPS)-stimulated macrophages and a mouse model. By employing B4 as a molecular probe, evidence is found for a previously explored role of HDAC7 that surpasses its deacetylase function, suggesting broader implications in inflammatory processes. Mechanistic investigations reveal the critical involvement of HDAC7 in the Toll-like receptor 4 (TLR4) signaling pathway by directly interacting with the TNF receptor-associated factor 6 and TGFβ-activated kinase 1 (TRAF6-TAK1) complex, thereby initiating the activation of the downstream mitogen-activated protein kinase/nuclear factor-κB (MAPK/NF-κB) signaling cascade and subsequent gene transcription. This study expands the insight into HDAC7's role within intricate inflammatory networks and highlights its therapeutic potential as a novel target for anti-inflammatory treatments.
IIa 类组蛋白去乙酰化酶(Class IIa HDACs)在调节重要的细胞代谢和炎症途径中发挥着关键作用。然而,当前抑制剂的泛抑制作用以及缺乏用于探测除表观遗传调控之外的功能的工具,阻碍了对每种 IIa 类 HDAC 同工型的具体作用的剖析。在这项研究中,开发了一种新型基于 PROTAC 的化合物 B4,它可选择性地靶向和降解 HDAC7,从而有效抑制脂多糖(LPS)刺激的巨噬细胞和小鼠模型中特定一组促炎细胞因子的表达。通过将 B4 用作分子探针,发现了先前探索的 HDAC7 的作用,其超越了其去乙酰化酶功能,这表明其在炎症过程中具有更广泛的意义。机制研究表明,HDAC7 通过直接与肿瘤坏死因子受体相关因子 6 和转化生长因子-β激活激酶 1(TRAF6-TAK1)复合物相互作用,在 Toll 样受体 4(TLR4)信号通路中起着关键作用,从而启动下游丝裂原活化蛋白激酶/核因子-κB(MAPK/NF-κB)信号级联和随后的基因转录的激活。这项研究扩展了对 HDAC7 在复杂炎症网络中的作用的认识,并强调了其作为新型抗炎治疗靶点的治疗潜力。